Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
Tue, 15.04.2025
More Impact AG
PRESS RELEASE
More Impact AG: Subsidiary BG Braingate Technology receives Notice of Allowance from the US Patent and Trademark Office for innovative technology
Frankfurt am Main, April 15, 2025 – More Impact AG (ISIN: DE000A1PG979, “More Impact”), a listed high-tech medical hub, announces that its subsidiary BG Braingate Technology GmbH (“Brainga [ … ]
Tue, 15.04.2025
LAIQON AG
Company Name:
LAIQON AG
ISIN:
DE000A12UP29
Reason for the research:
Update
Recommendation:
BUY
from:
15.04.2025
Target price:
EUR 7.40
Target price on sight of:
12 months
Last rating change:
Analyst:
Henry Wendisch
FY'24 review: improved cost mix ahead of AuM scalingTo recap: Following preliminary sales and EBITDA figures of M [ … ]
Tue, 15.04.2025
FRIWO AG
FRIWO achieves revised annual targets for 2024 – growth momentum expected from 2025
Group revenue of 93.0 million euros in 2024 within the forecast range
EBIT improved to -3.6 million euros year-on-year
Financial and strategic realignment is being consistently implemented
Positive momentum expected in 2025 – high revenue growth and a sustainable [ … ]
Tue, 15.04.2025
EXASOL AG
Exasol AG: Supervisory Board resolves early extension of CEO Jörg Tewes‘ contract
Nuremberg, 15 April 2025: The Supervisory Board of Exasol AG (ISIN DE000A0LR9G9, Xetra: EXL), a European technology company and provider of a high-performance analytics engine, has early extended the contract of Chief Executive Officer (CEO) Jörg Tewes until 31 Decemb [ … ]
Tue, 15.04.2025
CYPRUMED GmbH
Press Release
Cyprumed Enters License and Option Agreement with MSD for the Development of Oral Peptide Therapeutics
MSD obtains a Non-Exclusive License for Cyprumed’s delivery technology to develop oral peptide therapeutics
Cyprumed will be eligible to receive up to $493 million in upfront, development, regulatory and sales milestones
Innsbruc [ … ]
Tue, 15.04.2025
EMERAM Capital Partners GmbH
EMERAM achieves success in challenging market environment: four investments and one exit in 2024, double-digit growth expected in 2025
2024: four acquisitions and one successful exit
Portfolio company revenues increased by an average of 134 percent and the number of employees grew by 47 percent
Further double-digit growth expected in 2025
Munich [ … ]
Tue, 15.04.2025
Blue Elephant Energy GmbH
EQS-Media / 15.04.2025 / 09:00 CET/CEST
Hamburg, April 15, 2025 — Blue Elephant Energy GmbH (“BEE”), an independent power producer specializing in renewable energy, has acquired a majority stake in Solar215 GmbH (“Solar215”), a Hamburg-based developer focused exclusively on utility-scale BESS.
Founded in 2023, Solar215 concentrates on battery [ … ]
Tue, 15.04.2025
Carl Zeiss Meditec AG
Carl Zeiss Meditec achieves significant earnings increase in Q2 2024/25
Jena, April 15, 2025
In the second quarter of fiscal year 2024/25 ending March 31, 2025, Carl Zeiss Meditec AG (ISIN: DE0005313704) has achieved revenue of around EUR 560 million (previous year: EUR 472.1 million), based on preliminary data, an increase of around 19%. [ … ]
Tue, 15.04.2025
The Stepstone Group
EQS-Media / 15.04.2025 / 08:32 CET/CEST
Press release
Stepstone Salary Report: With these salaries, employees are considered top earners
Analysis of over 1 million salary data shows the top salaries in Germany
An annual income of 80,000 euros is enough for the top 10% – large regional differences
Top earners mainly in Hamburg, Hesse and th [ … ]
Tue, 15.04.2025
Pentixapharm Holding AG
Berlin, April 15, 2025 – The Management Board and Supervisory Board of Pentixapharm Holding AG today announced the following key resolutions:
The Group closed the 2024 financial year with a net loss of EUR 12.8 million, as reflected in the newly published annual financial statements.
Based on current planning, the Company expects a net loss of ap [ … ]